SOPHIA ANTIPOLIS, France – July 16, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring service. What’s new today? Spotlight on Emerging Innovators: The Strategic Value of Patent Monitoring The first half of 2025 confirms the ongoing momentum in therapeutic mRNA innovation, as highlighted in KnowMade’s press release[…]
SOPHIA ANTIPOLIS, France – July 11, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring service. What’s new today? Emerging Innovators in a Record-Setting Quarter for Therapeutic mRNA The continued innovation in therapeutic mRNA is confirmed through the first half of 2025, as reflected by KnowMade’s Therapeutic mRNA[…]
SOPHIA ANTIPOLIS, France – April 28, 2025 │ The therapeutic RNA landscape continues to evolve with a robust pace of innovation. The latest Q1 2025 edition of our Therapeutic mRNA patent monitor highlights significant developments in intellectual property activities, shedding light on key contributors and trends in this dynamic field. BioNTech, Sanofi, Penn, and Moderna[…]
SOPHIA ANTIPOLIS, France – February 04, 2025 │ KnowMade actively tracks therapeutic mRNA innovations as part of its Therapeutic mRNA patent monitoring services. What’s new today? CHMP Recommends Approval of KOSTAIVE® (ARCT-154) EMA opinion The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval[…]